Digest Network Come funziona
Network
/
Società
Ol
Non verificato

Ollin Biosciences, Inc.

Di cosa scriviamo

BiotecnologiaEventiIndustriaOtticaSalute

6 comunicati stampa

Guarda tutti i comunicati
02/06/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at Clinical Trials at the Summit 2026
Fonte
Ollin Biosciences, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Eventi
Biotecnologia
Farmaceutica
Ottica
Salute
Ollin Biosciences to Participate in Upcoming Investor Conferences
Fonte
Ollin Biosciences, Inc.
Emittente
Business Wire
1.00
0
08/04/2026
Eventi
Biotecnologia
Sanità
Ottica
Salute
Ollin Biosciences to Participate in Two Upcoming Investor Conferences
Fonte
Ollin Biosciences, Inc.
Emittente
Business Wire
1.00
0
30/03/2026
Industria
Salute
Medicina - Varie
Scienza
Ottica
Biotecnologia
Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Fonte
Ollin Biosciences, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Scienza
Biotecnologia
Farmaceutica
Ottica
Salute
Medicina - Varie
Eventi
Industria
Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
Fonte
Ollin Biosciences, Inc.
Emittente
Business Wire
1.00
0
17/09/2025
Scienza
Sanità
Farmaceutica
Ottica
Biotecnologia
Medicina - Varie
Salute
Industria
Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
Fonte
Ollin Biosciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0